On the other hand, based on the nature of a coreceptor of TLR4 (27–29) and the relationship with drug-resistance (35, 36), we speculated that MD2 could be a potential biomarker for the diagnosis and treatment of gliomas. Here, LY96 is linked to central nervous system cancer.